Vira Therapeutics - Crunchbase Company Profile & Funding

Q: Where is Vira Therapeutics's headquarters?

Vira Therapeutics is located in Innsbruck, Tirol, Austria.

Q: Who invested in Vira Therapeutics?

Vira Therapeutics has 3 investors including Boehringer Ingelheim Venture Fund And EMBL Ventures.

Q: When was the last funding round for Vira Therapeutics?

Vira Therapeutics closed its last funding round on obfuscated from a Series A round.

Q: How much funding has Vira Therapeutics raised to date?

Vira Therapeutics has raised obfuscated.

Overview

Vira Therapeutics

Total Funding

obfuscation

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Vira Therapeutics

CB Rank

752717

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic viruses.

Acquired by

Boehringer Ingelheim

Founded

obfuscation

Private

Series A

Innsbruck, Tirol, Austria

11-50

www.viratherapeutics.com/

Biotechnology

Health Care

Medical

Therapeutics

Funding Rounds

Series A

OBF

obfuscation

Key People

Dorothee Holm-von Laer: Co-Founder & CEO

Details

Legal Name

ViraTherapeutics GmbH

Operating Status

Active

Company Type

For Profit

Founders

Dorothee Holm-von Laer

About the Company

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical

trials in cancer patients.

Phone Number

+43512272061

Contact Email

office(@)viratherapeutics.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Modified Vesicular Stomatitis Virus (VSV-GP)

A new class of immunotherapy drug based on an oncolytic virus designed to selectively destroy cancer cells without harming normal tissues.

Preclinical safety and efficacy studies

Studies conducted to assess the safety and effectiveness of the Modified Vesicular Stomatitis Virus (VSV-GP) before proceeding to clinical trials.

Research & Development

Vira Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A
obfuscated obfuscation	Series A - Vira Therapeutics	3	obfuscated obfuscation	Boehringer Ingelheim Venture Fund, EMBL Ventures	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Boehringer Ingelheim Venture Fund	Yes	Series A - Vira Therapeutics	—
Boehringer Ingelheim Venture Fund	Yes	Series A - Vira Therapeutics	—
Boehringer Ingelheim Venture Fund	Yes	Series A - Vira Therapeutics	—
Boehringer Ingelheim Venture Fund	Yes	Series A - Vira Therapeutics	—
Boehringer Ingelheim Venture Fund	Yes	Series A - Vira Therapeutics	—